Adenovirus mediated CTLA4Ig gene inhibits infiltration of immune cells and cell apoptosis in rats after liver transplantation.

Ministry of Public Health, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China.
World Journal of Gastroenterology (Impact Factor: 2.55). 03/2005; 11(7):1065-9.
Source: PubMed

ABSTRACT To investigate the role of adenovirus-mediated CTLA4Ig gene therapy in inhibiting the infiltration of macrophages and CD8(+) T cells and cell apoptosis after liver transplantation.
The rat orthotopic liver transplantation model was applied. The rats were divided into three groups: group I: rejection control (SD-to-Wistar); group II: acute rejection treated with intramuscular injection of CsA 3.0 mg/(kg x d) for 12 d (SD-to-Wistar+CsA); groupIII: injection of 1 x 10(9) PFU adenovirus-mediated CTLA4Ig gene liquor in dorsal vein of penis 7 d before liver transplantation (SD-to-Wistar+CTLA4Ig). Immunohistochemistry and transferase-mediated dUTP nick-end labeling (TUNEL) were used to analyze the expression of CTLA4Ig gene in liver, infiltration of macrophages and CD8(+) T cells, cell apoptosis in grafts at different time-points after liver transplantation. Histopathological examination was done.
CTLA4Ig gene expression was positive in liver on d 7 after administering adenovirus-mediated CTLA4Ig gene via vein, and remained positive until day 60 after liver transplantation. Infiltration of macrophages and CD8(+) T cells in CTLA4Ig-treated group was less than in rejection control group and CsA-treated group. The apoptotic index of rejection group on d 3, 5, and 7 were significantly higher than that of CTLA4Ig-treated group. A good correlation was found between severity of rejection reaction and infiltration of immune activator cells or cell apoptotic index in grafts.
CTLA4Ig gene is constantly expressed in liver and plays an important role in inducing immune tolerance.

0 0
  • [show abstract] [hide abstract]
    ABSTRACT: Host immune responses play a major role in clearance of viral infections from the body, and may limit long-term expression and clinical efficacy of viral vectors. Methods to prevent these immune responses may also increase the risk for infections, recombination with wild type virus and affect biodistribution, persistence, shedding and transmission. The study described in this report was initiated to assess possible environmental risks associated with the use of immune modulation in combination with gene therapy and set up as a literature study, by performing PubMed searches for certain keywords, by interviewing experts and by attending selected meetings. Lack of availability of clinical data combining gene therapy and immune modulation and limited animal data warranted additional exploration of relevant non-gene therapy studies from closely related fields such as stem cell and organ transplantation, and vaccination studies with live attenuated vaccines. ...... Finally, we propose the use of a checklist to assess current environmental risks in the use of immune modulation during gene therapy. This report is expected to provide guidance to risk assessors and regulatory officers as well as to applicants for a gene therapy licence.
    Annals of Hematology - ANN HEMATOL. 01/2010;
  • [show abstract] [hide abstract]
    ABSTRACT: Organ transplantation represents the only definitive therapy for many causes of end-organ failure. However, the universal success of this therapy is limited by chronic allograft rejection, the side effects of chronic immunosuppressive therapy, and a severe shortage of donor organs. Presently, the success of solid-organ transplantation depends on the continuous administration of toxic and nonspecific immunosuppressive agents, therapies that present risks for opportunistic infection, malignancy, and a variety of agent-specific side effects. To promote the use of transplantation with limited risk of long-term sequelae, three dominant research challenges emerge: (i) elimination of the need for exogenous immunosuppression by immunological tolerance induction; (ii) prevention of chronic rejection/graft dysfunction; and (iii) expansion of available organs for transplantation. Gene therapy may provide significant advances and solutions in each of these areas. Rejection of the graft in the immediate post-transplant period has been attacked through the transfer of immunomodulatory molecules in addition to tolerance inducing approaches. Chronic graft rejection may be similarly addressed through permanent tolerance induction or alternatively through the introduction of molecules to resist chronic graft damage. Genetic manipulation of stem cells may ultimately produce transgenic animals to serve as tissue donors to overcome the limited donor organ supply. This review will highlight ongoing developments in the translation of gene therapy approaches to the challenges inherent in transplantation.
    Transplant International 07/2006; 19(6):435-45. · 3.16 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: It is increasingly clear that, regardless of etiology, inflammatory and immunological mechanisms are involved in the pathogenesis of virtually all hepatobiliary diseases and hepatic fibrogenesis. Studies of immunopathogenetic mechanisms have identified multiple therapeutic targets in both the innate and adaptive immune responses that portend the future ability to prevent hepatic allograft rejection and control progression of chronic viral hepatitis, alcoholic and nonalcoholic fatty liver disease, drug-induced hepatotoxicity, graft-versus-host disease (GVHD), and autoimmune and immune-mediated inflammatory diseases (IMIDs) of the liver. The current availability of multiple immunosuppressive and anti-inflammatory drugs with distinct, complementary sites of action provides the opportunity and impetus to study their therapeutic potentials in both transplant and nontransplant settings. Concurrent immunosuppression of several specific sites involved in immunopathogenesis may ultimately enhance efficacy, while minimizing the dosedependent toxicities of individual drugs. Thus, the goals of this chapter are to review the mechanism(s) of action of established and new immunosuppressive and anti-inflammatory agents and to discuss their current and future therapeutic potentials in the prevention of hepatic allograft rejection and nontransplant hepatobiliary diseases.
    12/2006: pages 391-407;


Available from